Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
By SquaredTown on July 1, 2025
NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...